DEADLINE NEXT WEEK: Berger Montague Advises SCYNEXIS, Inc. (SCYX) Investors to Contact the Firm Before January 8, 2024

Philadelphia, Pennsylvania--(Newsfile Corp. - January 4, 2024) - Berger Montague announces that a class action lawsuit was filed in the U.S. District Court for the District of New Jersey on behalf of those who acquired SCYNEXIS, Inc. ("Scynexis") (NASDAQ: SCYX) securities.

If you suffered losses as a result of your investment in Scynexis (NASDAQ: SCYX) and would like to learn about a potential recovery, CLICK HERE.

The lawsuit has been filed against Scynexis on behalf of purchasers of Scynexis's securities between March 31, 2023 and September 22, 2023, inclusive (the "Class Period").

The deadline for Investors who purchased or acquired Scynexis securities during the Class Period to seek to be appointed as a lead plaintiff representative of the class is January 8, 2024.

The Class Period commences on March 31, 2023, when Scynexis filed a Form 10-K for the period ended December 31, 2022 (the "2022 10-K"). The 2022 10-K attested to the fact that, "as of December 31, 2022, our disclosure controls and procedures were effective at the reasonable assurance level."

The lawsuit alleges that the truth regarding the Company emerged on September 25, 2023, when Scynexis announced that it "became aware that a non-antibacterial beta-lactam drug substance is manufactured using equipment common to the manufacturing process for ibrexafungerp." As a result, Scynexis recalled BREXAFEMME® (ibrexafungerp tablets) from the market and put a temporary hold in ibrexafungerp clinical studies "until a mitigation strategy and a resupply plan are determined."

Following this news, Scynexis's shares fell $1.13, or 34.14%, to close at $2.18 per share on September 25, 2023. The stock price continued to fall the next trading session by 11.47%, to close at $1.93 per share on September 26, 2023.

For additional information or to learn how to participate in this litigation, please contact Berger Montague: James Maro at jmaro@bm.net or (267) 637-3176, or Andrew Abramowitz at aabramowitz@bm.net or (215) 875-3015 or CLICK HERE.

A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not, however, affected by the decision whether or not to serve as a lead plaintiff. Communicating with any counsel is not necessary to participate or share in any recovery achieved in this case. Any member of the purported class may move the Court to serve as a lead plaintiff through counsel of his/her choice, or may choose to do nothing and remain an inactive class member.

Berger Montague, with offices in Philadelphia, Minneapolis, Delaware, Washington, D.C., San Diego, San Francisco and Chicago, has been a pioneer in securities class action litigation since its founding in 1970. Berger Montague has represented individual and institutional investors for over five decades and serves as lead counsel in courts throughout the United States.

Contacts:
James Maro, Senior Counsel
Berger Montague
(267) 637-3176
jmaro@bm.net

Andrew Abramowitz, Senior Counsel
Berger Montague
(215) 875-3015
aabramowitz@bm.net

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/193192